Skip to content

The Incretin Effect in Patients With Gestational Diabetes Mellitus

Observational Study to Evaluate the Reduced Incretin Effect Observed in Patients With GDM in Relation to Reversibility After a Delivery.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01307995
Enrollment
20
Registered
2011-03-03
Start date
2007-04-30
Completion date
2010-05-31
Last updated
2011-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gestational Diabetes

Keywords

GDM, incretin effect, gestation, reversibility

Brief summary

The aim of this study is to evaluate the reduced incretin effect observed in patients with T2DM in relation to reversibility. The incretin effect will be measured by means of OGTT and iIVGTT in 12 women with GDM during pregnancy (third trimester), and again 2-3 months post partum. It is anticipated that the incretin effect in patients with GDM is reduced - like in patients with other forms of DM. The investigators estimate that approximately 90 % of the patients with GDM re-establish a NGT 2-3 months post partum. This particular group of patients provides a unique possibility for demonstrating the reversibility of the reduced incretin effect in relation to optimal glycaemic control.

Interventions

None listed

Sponsors

University of Copenhagen
CollaboratorOTHER
Medical University of Lodz
Lead SponsorOTHER

Study design

Observational model
CASE_CROSSOVER

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* age above 18 years old * GDM diagnosed according to WHO guidelines (GDM group) or ruled out by OGTT 75g (Control group)

Exclusion criteria

* Previous diagnosis of DM * Positive GAD-65-autoantibodies and/or positive islet cell autoantibodies (ICA) * Affected biochemical liver parameters (ALAT \> 2 times normal upper range) * Affected biochemical kidney parameters (se-creatinine \> 130 µM) * Treatment with medicine interacting with insulin secretion (e.g. steroids) * Treatment with medicine that can not be paused for 16 hours

Countries

Poland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026